TP 0591108
Alternative Names: TP-0591108Latest Information Update: 13 Oct 2025
At a glance
- Originator Taisho Pharmaceutical
- Class Antifibrotics; Skin disorder therapies
- Mechanism of Action Lysophosphatidic acid receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Systemic scleroderma